^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | paxalisib (GDC-0084) (mTOR inhibitor, PI3K inhibitor, AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
427 / 22 - Newer generation mTOR inhibition represents effective therapeutic strategy for BRAF-mutant melanoma
Published date:
03/15/2023
Excerpt:
The dual PI3K/mTORC inhibitor, Paxalisib, significantly reduced cell proliferation greater than combination AKT/SGK inhibition and resulted in increased overall survival in a BRAF-driven immunocompetent mouse model of melanoma (p=0.0003 vs vehicle).
